| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 80.92 Billion |
| Market Size (2030) | USD 96.53 Billion |
| CAGR (2025 - 2030) | 3.59 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Pain Management Market Analysis
The Pain Management Market size is estimated at USD 80.92 billion in 2025, and is expected to reach USD 96.53 billion by 2030, at a CAGR of 3.59% during the forecast period (2025-2030).
The COVID-19 pandemic has impacted healthcare systems across the world. Health agencies were involved in containing coronavirus transmission through lockdown norms, and most elective and non-urgent surgeries were postponed globally. As per the Indian Journal of Anaesthesia 2020, COVID-19 negatively impacted pain clinics, including interventional pain management procedures. The Indian Society of Anaesthesiologists also published guidelines on anesthesia and intensive care practices. Also, the Journal of Pain Medicine suggested that epidural nonsteroid injections for radicular pain can be considered in patients who are already immunosuppressed and at high risk of SARS-CoV-2 infection and complications. As per the April 2022 data published by PubMed, it was observed that people across the United States and Canada suffering from chronic pain witnessed a significant increase in pain during the pandemic. However, following the pandemic, effective pain management services are practiced among people suffering from chronic pain, as restrictions on non-essential hospital visits are lifted. Hence, it is observed that the current pain industry has reached a pre-pandemic nature.
The well-established business of using painkiller medications as the first line of treatment has significantly contributed to the growth of the pain management market. However, in recent years, the growing reliance on their long-term use, as well as a better understanding of their side effects, has led to an increase in the use of device-based therapies, contributing to the growth of the pain management devices market. Post-operative pain is one of the most common. The cost of monitoring and treating adverse effects creates a significant demand for pain management drugs and devices.
The current market is gradually adopting more non-opioid medications as alternative pain management solutions to suppress the addiction to opioids and other well-established painkillers on the market. Several non-opioid drugs with mechanisms of action are currently in the early and late stages of development. The regulatory authorities in multiple countries are shifting to alternative approaches, thus fast-tracking those drugs to market approval. The shift is expected to be gradual. Thus, pain management has desirable growth prospects during the forecast period.
The increasing aging population globally is expected to drive the market's growth, as the prevalence of chronic pain is relatively high among the geriatric population and is considered an independent risk factor for mortality. The increasing number of product launches is also expected to drive the market. For instance, in October 2021, Esteve Pharmaceuticals received approval from the US FDA for SEGLENTIS (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Thus, due to such factors, the pain management market is expected to grow significantly over the forecast period.
However, high procedural and purchase costs of devices in the pain management devices market can restrain the market's growth.
Pain Management Market Trends
Facial Pain and Migraine Segment is Expected to Exhibit a Significant Growth Rate During the Forecast Period
Headache and facial pain are among the few frequent complaints in the emergency and outpatient settings. Most patients who present themselves with headaches have one of the following three main headache syndromes: migraine, cluster headache, or tension headache.
The Migraine Research Foundation updated in 2021 that migraine is an extraordinarily prevalent neurological disease, affecting about 39 million men, women, and children in the United States and 1 billion worldwide. Migraine is considered the third-most prevalent illness in the world. According to the Cleveland Clinic update in 2021, migraine is also the sixth-most disabling illness in the world. For every 10 seconds, someone in the United States goes to the emergency room complaining of a headache, and approximately 1.2 million visits are for acute migraine attacks. Hence, the high prevalence of migraine is expected to propel the growth of the pain management market in the coming years.
Furthermore, the burden of headaches and migraine is found to be the same across the world, and every day, the percentage of people suffering from migraine/headaches increases. For instance, according to the article published in the JAMA Network in January 2022, in the United States, 17.1% of women and 5.6% of men reported having migraine symptoms. Thus, the high prevalence of migraine is expected to boost the pain management therapeutics market. Moreover, several companies are launching new products in the market, leading to the growth of the segment studied and the expansion of the pain management drugs market. In February 2022, Biohaven Pharmaceutical Holding Company Ltd and Pfizer Inc. reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. Hence, such new launches and high prevalence of pain, the segment is expected to witness strong growth in coming years.
In addition, the increasing burden of cancer is also contributing largely to facial pain and headache, which is a fueling factor for the segment's growth and the cancer pain management market.
Understand The Key Trends Shaping This Market
Download PDF
North America Captured the Largest Market Share and is Expected to Retain its Dominance During the Forecast Period
North America holds the largest share of the pain management market, with the United States being the most significant contributor to its revenue. Factors such as increasing demand for long-term pain management from the geriatric population and developments in the pain management industry are expected to boost the market growth in North America.
Moreover, according to PubMed data from 2022, the prevalence of chronic pain in Americans is increasing. Every year, one out of five people suffers from chronic pain in the region. Since it is one of the most common chronic conditions in the United States, there is a growing demand for pain management services across the country. Furthermore, according to the recommendations provided by the American Society of Regional Anesthesia and Pain Medicine (ASRA), chronic opioid therapy and the use of steroids in interventional pain management procedures may induce immune suppression, which is very critical as it minimizes the chances of fighting several viral infections. Hence, all the aforesaid factors are expected to increase the demand for pain management devices and drugs over the forecast period.
Overall, the U.S. pain management drugs market is considered highly competitive, primarily due to the significant presence of pain specialist physicians, the increasing trend of product approvals from the FDA, and the robust infrastructure for providing pain management services to patients. For instance, in November 2021, Biohaven Pharmaceutical Holding Company Ltd and Pfizer Inc. formed a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval. Rimegepant is commercialized as Nurtec ODT in the United States and is indicated for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults. Thus, the market is expected to grow significantly in North America over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
Pain Management Industry Overview
The pain management market is highly competitive and consists of several major players. The existing pain management companies employ strong competitive strategies, leading to intense competition. Some of the key players in the pain management industry are Abbott Laboratories, Johnson & Johnson, Baxter International Inc. (Avante Health Solutions), Becton, Dickinson and Company, and Boston Scientific Corporation, among others.
Pain Management Market Leaders
-
Abbott Laboratories
-
Becton, Dickinson and Company
-
Boston Scientific Corporation
-
Johnson and Johnson
-
Baxter International Inc. (Avante Health Solutions)
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Pain Management Market News
- October 2022: Parker Laboratories Inc., which develops, manufactures, and sells pain relief creams, ultrasound and electromedical contact media, and institutional cleaners and disinfectants, is expanding its analgesics line. The company has added Helix CBD Therapy Cream, CBD Clinical Cream, and Tri-Active Therapy Cream to its HelixTM line.
- September 2022: Compass Group Equity Partners, a St. Louis-based private equity firm, announced a strategic partnership with Mays & Schnapp Neurospine and Pain ("Mays & Schnapp"), a Memphis-based interventional pain management practice serving patients in Tennessee and Mississippi.
- July 2021: Venus Remedies Limited has launched a consumer healthcare division that will offer various products for pain management.
- January 2021: Boston Scientific Corporation launched the WaveWriter Alpha, a portfolio of spinal cord stimulator (SCS) systems that combine therapy options for personalized pain relief.
Pain Management Industry Segmentation
Pain is an unpleasant sensation in the body due to ongoing or impending tissue damage. Pain management includes therapies, drugs, and devices that help alleviate the pain. The pain management market is segmented by mode of pain management (drugs and devices), drugs is further sub-segmented by (opioids and non-narcotic analgesics), and non-narcotic is sub-sub-segmented by (non-steroidal anti-inflammatory drugs, anesthetics, anticonvulsants, anti-depressants, and other non-narcotic analgesics), devices is sub-segmented by (neurostimulation devices and analgesic infusion pumps), neurostimulation devices is sub-sub-segmented by (transcutaneous electrical nerve stimulation devices and brain and spinal cord stimulation devices), and analgesics infusion pumps is sub-sub-segmented by (intrathecal infusion pumps and external infusion pumps), by application (neuropathic pain, cancer pain, facial pain and migraine, musculoskeletal pain, and other applications), and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| BY Mode of Pain Management | Drugs | Opioids | ||
| Non-narcotic Analgesics | Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) | |||
| Anesthetics | ||||
| Anticonvulsants | ||||
| Anti-depressants | ||||
| Other Non-narcotic Analgesics | ||||
| Devices | Neurostimulation Devices | Transcutaneous Electrical Nerve Stimulation (TENS) Devices | ||
| Brain and Spinal Cord Stimulation (SCS) Devices | ||||
| Analgesic Infusion Pumps | Intrathecal Infusion Pumps | |||
| External Infusion Pumps | ||||
| By Application | Neuropathic Pain | |||
| Cancer Pain | ||||
| Facial Pain and Migraine | ||||
| Musculoskeletal Pain | ||||
| Other Applications | ||||
| Geography | North America | United States | ||
| Canada | ||||
| Mexico | ||||
| Europe | Germany | |||
| United Kingdom | ||||
| France | ||||
| Italy | ||||
| Spain | ||||
| Rest of Europe | ||||
| Asia-Pacific | China | |||
| Japan | ||||
| India | ||||
| Australia | ||||
| South Korea | ||||
| Rest of Asia-Pacific | ||||
| Middle East and Africa | GCC | |||
| South Africa | ||||
| Rest of Middle East and Africa | ||||
| South America | Brazil | |||
| Argentina | ||||
| Rest of South America | ||||
Need A Different Region or Segment?
Customize Now
Pain Management Market Research FAQs
How big is the Pain Management Market?
The Pain Management Market size is expected to reach USD 80.92 billion in 2025 and grow at a CAGR of 3.59% to reach USD 96.53 billion by 2030.
What is the current Pain Management Market size?
In 2025, the Pain Management Market size is expected to reach USD 80.92 billion.
Who are the key players in Pain Management Market?
Abbott Laboratories, Becton, Dickinson and Company, Boston Scientific Corporation, Johnson and Johnson and Baxter International Inc. (Avante Health Solutions) are the major companies operating in the Pain Management Market.
Which is the fastest growing region in Pain Management Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Pain Management Market?
In 2025, the North America accounts for the largest market share in Pain Management Market.
What years does this Pain Management Market cover, and what was the market size in 2024?
In 2024, the Pain Management Market size was estimated at USD 78.01 billion. The report covers the Pain Management Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Pain Management Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Pain Management Industry Report
The global pain management market is poised for substantial growth, driven by increasing chronic pain incidence and advancements in pain management devices and medications. The market offers a variety of treatments such as NSAIDs, anticonvulsants, and narcotics, effectively addressing conditions like neuropathic pain, cancer pain, and musculoskeletal pain, with significant growth observed in the musculoskeletal segment. Furthermore, the industry is shifting towards non-opioid medications due to regulatory changes promoting safer alternatives. Device-based therapies, including spinal cord stimulators and wearable technology, are also gaining popularity for their long-term efficacy and minimal side effects. Dominantly, over-the-counter sales lead the distribution channels, supported by prescription-based solutions that tailor to specific patient needs. Geographically, North America leads the market with its advanced medical infrastructure, while Asia-Pacific is expected to witness the fastest growth. For comprehensive market insights, including detailed statistics and growth prospects, a full report by Mordor Intelligence™ is available for free download.
